- In September 2024, Samyang Corporation held a groundbreaking ceremony for its new Specialty Plant in Ulsan, committing approximately USD 105 million to the project. The facility will house South Korea’s largest allulose production plant with an annual capacity of 13,000 tons, alongside a prebiotics production unit manufacturing resistant dextrin and fructo-oligosaccharide powder. This expansion marks a strategic move by Samyang to enhance its footprint in North America, Japan, and Southeast Asia’s health-oriented ingredient markets
- In January 2024, the biotics sector experienced several key updates, including progress toward establishing postbiotic standards in China and rising demands for stricter probiotic regulations in Hong Kong. These developments highlight the growing need for regulatory clarity and quality control within the global biotics industry
- In November 2023, Ting Li Development, the investment arm of Ting Hsin International Group which commands nearly 35% of China’s instant food and beverage market—entered a strategic alliance focused on reducing sugar and carbohydrate levels in its product portfolio. This collaboration reflects the increasing industry emphasis on health-conscious formulations in the Asian F&B sector
- In June 2023, Sanofi partnered with AB-BIOTICS to launch a line of probiotics aimed at improving cholesterol levels for consumers in South Korea. This initiative underscores the role of functional supplements in addressing prevalent health concerns in the Asian market
